Impact of new clinical trials on recent guidelines on hypertension management

Annals of Medicine

Volumn 43, Issue 2, 2011, Pages 124-132

  Mancia, Giuseppe ^a   Grassi, Guido ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Antihypertensive treatment; clinical trials; guidelines

Indexed keywords

GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; OLMESARTAN; RAMIPRIL; TELMISARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); HUMAN; HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TARGET ORGAN;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; EUROPE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC;

EID: 79951573242     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.543922     Document Type: Article

References (41)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-87.
2. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59. (Pubitemid 351522739)
3. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al.; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225-37.
4. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-recep-tor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372: 1174-83.
5. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575-85.
6. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72. (Pubitemid 351831357)
7. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98. (Pubitemid 351620109)
8. Jamerson K, Weber MA, Bakris GL, Dahl ö f B, Pitt B, Shi V, et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-28.
9. Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, et al. Prevention of microalbuminuria in type 2 diabetes (ROADMAP TRIAL). J Hypertens. 2010;28(e-suppl):e233.
10. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfi eld MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009; 27:2121-58.
11. Reaven G. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diab Vasc Dis Res. 2005;2:105-12. (Pubitemid 41695168)
12. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113-32.
13. Mancia G, Lanfranchi A, Turri C, Grassi G. Can good surrogate end-points predict the prognosis of hypertensive patients? J Hypertens Suppl. 1998;16:S3-S7. (Pubitemid 28550204)
14. Mancia G, Grassi G. The new European Society of Hypertension / European Society of Cardiology Guidelines. Ther Adv Cardiovasc Dis. 2008;2:5-12. (Pubitemid 351583138)
15. Vasan RS, Larson MG, Leip EP, Evans JC, O ' Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345: 1291-7.
16. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in offi ce, home, and ambulatory blood pressure. Hypertension. 2006;47:846-53. (Pubitemid 44297554)
17. Verberk W, Kroon AA, de Leeuw PW. Masked hypertension and white-coat hypertension prognosis. J Am Coll Cardiol. 2006;47:2127.
18. Mancia G. Blood pressure reduction and cardiovascular outcomes: past, present, and future. Am J Cardiol. 2007;100: 3J-9J.
19. Grassi G. Sympathetic deactivation as a goal of nonphar-macologic and pharmacologic antihypertensive treatment: rationale and options. Curr Hypertens Rep. 2003;5:277-80. (Pubitemid 38898949)
20. Hypertension: management of hypertension in adults in primary care NICE/BHS. June 2006. Available at: www.nice. org.uk/CG034.
21. Sica DA. Chlorthalidone - a renaissance in use? Expert Opin Pharmacother. 2009;10:2037-9.
22. Neff KM, Nawarskas JJ. Hydrochlorothiazide versus chlorthalidone in the management of hypertension. Cardiol Rev. 2010;18:51-6.
23. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3-10. (Pubitemid 41819128)
24. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26:819-24. (Pubitemid 351354932)
25. Lever AF, Beevers DG, Hole DJ, Isles CG, Meredith PA, Murray LS, et al. Mortality amongst patients of the Glasgow Blood Pressure Clinic was high in the 1970s and 80s but has fallen since, why? Clin Exp Hypertens. 1999;21: 553-62. (Pubitemid 29325457)
26. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ. 1998;317:167-71. (Pubitemid 28325537)
27. Mancia G. Role of outcome trials in providing information on antihypertensive treatment: importance and limitations. Am J Hypertens. 2006;19:1-7. (Pubitemid 43217024)
28. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002;20: 1461-4. (Pubitemid 34921162)
29. Mancia G, Bombelli M, Lanzarotti A, Grassi G, Cesana G, Zanchetti A, et al. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med. 2002;162:582-86. (Pubitemid 34193546)
30. Mancia G, Pessina AC, Trimarco B, Grassi G; SILVIA (Studio Italiano Longitudinale sulla Valutazione della Iperten-sione Arteriosa nel 2000) Study Group. Blood pressure control according to new guidelines targets in low to high-risk hypertensives managed in specialist practice. J Hypertens. 2004;22:2387-96. (Pubitemid 39620289)
31. Mancia G, Ambrosioni E, Rosei EA, Leonetti G, Trimarco B, Volpe M; ForLife study group. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens. 2005;23:1575-81. (Pubitemid 41104830)
32. Mancia G, Parati G, Borghi C, Ghironzi G, Andriani E, Marinelli L, et al. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens. 2006;24:837-43. (Pubitemid 43670453)
33. Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Baurecht H, et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 2007;25:1087-94. (Pubitemid 46573129)
34. Conroy RM, Py ö r ä l ä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
35. Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, et al.; LIFE Study Investigators. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). Circulation. 2009;119:1883-91.
36. Li Z, Dahl ö f B, Okin PM, Kjeldsen SE, Wachtell K, Ibsen H, et al. Bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. J Hypertens. 2008;26:1244-9.
37. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290:2805-16. (Pubitemid 37509488)
38. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-31. (Pubitemid 38781102)
39. Bangalore S, Messerli FH, Wun C, Zuckerman AL, DeMicco D, Kostis JB, et al.; Treating to New Targets Steering Committee and Investigators. J-Curve revisited: an analysis of the Treating to New Targets (TNT) Trial. J Am Coll Cardiol. 2009;53:A217.
40. Bakris GL, Sarafi dis PA, Weir MR, Dahl ö f B, Pitt B, Jamerson K, et al.; ACCOMPLISH Trial investigators. Renal outcomes with different fi xed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecifi ed secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173-81.
41. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20:1813-21.